1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Restless Legs Syndrome - Pipeline Review, H1 2017

Restless Legs Syndrome - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 42 pages

Restless Legs Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome – Pipeline Review, H1 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf’s or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 1 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Restless Legs Syndrome - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome - Overview
Restless Legs Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Restless Legs Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restless Legs Syndrome - Companies Involved in Therapeutics Development
Galenica Ltd
Hisamitsu Pharmaceutical Co Inc
Merz Pharma GmbH and Co KgaA
Mundipharma International Ltd
Omeros Corp
Serina Therapeutics Inc
Restless Legs Syndrome - Drug Profiles
(naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
aplindore fumarate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ropinirole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SER-214 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Restless Legs Syndrome - Dormant Projects
Restless Legs Syndrome - Discontinued Products
Restless Legs Syndrome - Product Development Milestones
Featured News and Press Releases
May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs
Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome
Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome
Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Restless Legs Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Restless Legs Syndrome - Pipeline by Galenica Ltd, H1 2017
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
Restless Legs Syndrome - Pipeline by Merz Pharma GmbH and Co KgaA, H1 2017
Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H1 2017
Restless Legs Syndrome - Pipeline by Omeros Corp, H1 2017
Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H1 2017
Restless Legs Syndrome - Dormant Projects, H1 2017
Restless Legs Syndrome - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Restless Legs Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.